Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis | NEJM

nejm.org - The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown. We evaluated u…

Tweeted by @DOMSinaiNYC https://twitter.com/DOMSinaiNYC/status/1177212053825695744